Annual Evaluation and Performance Measurement Report (I.13- ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) OF INVASIVE *HAEMOPHILUS INFLUENZAE (H. INFLUENZAE)* IN JURISDICTION)

Annually, each funded laboratory is required to report to CDC evaluation and performance measures. Data are used to indicate progress made toward program outcomes. These summary reports have to be uploaded to the ELC CAMP at the end of each funding year. Required performance measures are listed below.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. **Susceptibility of invasive H. influenzae ( HI) isolates using broth microdilution, according to the Clinical & Laboratory Standards Institute (CLSI) guidelines for at least the following 12 antibiotics with QC-passed broth microdilution test results:**  |  |  | | --- | --- | | **Antibiotic:** | **Total Number (N) of H. influenzae Isolates** **with QC-passed broth microdilution** | | 1. **Rifampin** |  | | 1. **Ampicillin** |  | | 1. **Amoxicillin-clavulanate** |  | | 1. **Chloramphenicol** |  | | 1. **Cefotaxime** |  | | 1. **Ceftriaxone** |  | | 1. **Cefuroxime** |  | | 1. **Clarithromycin** |  | | 1. **Levofloxacin** |  | | 1. **Meropenem** |  | | 1. **Tetracycline** |  | | 1. **Trimethoprim-sulfamethoxazole** |  | |
| 1. **Proportion of isolates with AST results reported to submitting sites within 3 weeks of submission:** 2. Numerator: Number of isolates with AST results reported to submitting sites within 3 weeks of submission 3. Denominator: Number of HI isolates received at AR Lab Network 4. Calculated: Percentage of isolates with AST results reported to sentinel sites within 3 weeks of submission |
| 1. **Proportion of isolates with AST results reported to CDC-Bacterial Meningitis Laboratory (CDC-BML) quarterly:**   a. Numerator: Number of isolates with AST results reported to CDC quarterly.  b. Denominator: Number of HI isolates received at AR Lab Network.  c. Calculated: Percentage of isolates with AST results reported to CDC quarterly. |
| 1. **Proportion of isolates transported to CDC-BML within 6 months:** 2. Numerator: Number of isolates transported to CDC 3. Denominator: Total number of HI isolates received at AR Lab Network. 4. Calculated: Percent of isolates transported to CDC within 6 months |